Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KgA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate Kuvan; expectations regarding the Kuvan expanded access program; expectations regarding filings with regulatory agencies; and the development of 6R-BH4 for other indications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of ongoing clinical trials related to Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities concerning Kuvan; results and timing of current and planned clinical trials of 6R-BH4 for other indications; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...
(Date:5/21/2013)... May 21, 2013 Two-thirds of patients ... cell lung cancer reported that they engage in at ... use, according to new findings from the National ... Kantar Health . The research will be presented today ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
(Date:5/21/2013)... 2013 A plastic surgery Internet ... plastic surgery SEO services following an Internet survey. ... name the “Best Plastic Surgery SEO Services”. , ... was predictable. Well-known in the plastic surgery Internet ... than any other selection based on superior client ...
(Date:5/21/2013)... May 21, 2013 It’s nearly summer and ... camp or starting practice for summer or fall sports. ... or sporting activities can begin. , To help parents ... for youth sports or camp physicals at just ... will review a child’s medical history, perform a physical exam ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3
... release is available in French . ... could be closer to reality, thanks to a discovery ... Hospital Research Centre. According to a study published in ... have become the first to clone, produce and purify ...
... patients with weakened immune systems. So it would seem ... prime breeding ground for infections because of the constantly ... whom could be exposed to bacteria and viruses at ... among the most common causes of illness and death ...
... Technology from Xiotech Selected by National Provider ... Minn., March 17 Xiotech Corporation today ... Emprise(TM) 7000 storage system, powered by Intelligent ... virtualization initiative. Milliman Care Guidelines will use ...
... 17 Siemens Energy & Automation, Inc. ... Mass., has selected Simatic(R) PCS 7 Lab ... manage pre- and post-clinical experimental data.(Logo: ... therapeutics based upon their novel polymeric nanoparticle ...
... (Hologic or the Company) (Nasdaq: HOLX ), ... medical imaging systems and surgical products dedicated to serving ... release its second quarter fiscal 2009 operating results on ... with the release, management will host a conference call ...
... Psychiatry , published by Elsevier, is very pleased to ... devoted to fundamental new insights into epigenetics, a field ... produce long-lasting or even heritable changes in gene function ... epigenetics in psychiatry promises several key advances, as noted ...
Cached Medicine News:Health News:Researchers clone key sperm-binding proteins 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 3Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 4Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 2Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 3Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 4Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 2Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 3Health News:Hologic to Release Second Quarter Fiscal 2009 Operating Results on Monday, May 4, 2009 2Health News:Understanding mental illness through gene-environment interactions 2
... long-life Active RFID tags using the wireless ... mobile assets or people, AeroScout enables the ... many different assets for the purpose of ... T2 Tag can be programmed via a ...
... Labels have a direct thermal print ... Tag-it™ HF-I transponder. When processed through ... and other graphics may be printed ... is programmed to the RFID transponder. ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending solution ... embedded in a smart label to ... prevent wrong-patient, wrong-site, wrong-procedure surgery. This ... by an orthopedic surgeon with the ...
Medicine Products: